Viking Therapeutics registers Phase 3 trial of VK2735 for weight management in type 2 diabetes
The study plans to enroll 560 participants and is expected to begin on October 16, 2026. It plans to evaluate oral VK2735 for weight management in adults with type 2 diabetes who are obese or overweight.
Primary source
ClinicalTrials.gov registry record, October 9, 2026
Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2)
Read the source: Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2) clinicaltrials.gov
Machine-summarized from the source above; not independently reported. How we use automation